Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 19/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 9/20 | 0.52 |
| ▸ | AURKA | O14965 | 8/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.52 |
| ▸ | JAK2 | O60674 | 2/20 | 0.50 |
| ▸ | CHUK | O15111 | 1/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18773838 | 0.86 | PDPK1 (0.55) | PDPK1TGFBR1AURKAAURKBROCK1 | |
| SCHEMBL15676705 | 0.84 | PDPK1 (0.53) | PDPK1TGFBR1AURKAAURKBROCK1 | |
| SCHEMBL15676695 | 0.83 | PDPK1 (0.52) | PDPK1TGFBR1AURKAAURKBROCK1 | |
| SCHEMBL24427531 | 0.78 | PDPK1 (0.52) | PDPK1TGFBR1AURKAAURKBROCK1 | |
| SCHEMBL15676757 | 0.77 | PDPK1 (0.55) | PDPK1TGFBR1AURKAAURKBROCK1 | |
| SCHEMBL24427251 | 0.76 | MAPK14 (0.39) | TGFBR1AURKBROCK1JAK2KDR | |
| SCHEMBL15676713 | 0.75 | PDPK1 (0.52) | PDPK1TGFBR1AURKAAURKBROCK1 | |
| SCHEMBL15676702 | 0.75 | PDPK1 (0.52) | PDPK1TGFBR1AURKAAURKBROCK1 | |
| SCHEMBL24427524 | 0.75 | SCN9A (0.46) | AURKBKDRSYK | |
| SCHEMBL17832298 | 0.74 | KDM4E (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) | 2022-12-06 | — | — | US | disclosed |
| EP-3998263-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | TFPI, TFPI2, F11 | PDPK1 2383/4885TGFBR1 2534/4885AURKA 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.